BRIEF—EUSA Pharma sells critical care business to SERB Pharma

EUSA Pharma (today announced it has entered into a definitive agreement with France-headquartered SERB Pharmaceuticals for the sale of its critical care business.

The agreement represents a strategic milestone for both companies, completing EUSA’s transition into a rapidly growing biopharmaceutical company fully focused on oncology and rare diseases while further extending SERB’s broad portfolio of medicines for rare and life-threatening diseases and confirming the company's ambition to grow its positioning as a key speciality pharma player covering niche indications.

The agreement is subject to customary closing conditions and the companies anticipate completion in third-quarter 2018.

No financial terms of the transaction have been disclosed.

The transaction includes a portfolio of products, which are marketed across a range of countries, and EUSA’s field-based critical care sales teams in the UK, France, Netherlands, Belgium and Poland.

The portfolio is based around Collatamp, which is marketed for the prevention of infection during surgery across Europe and a wide range of countries outside the USA, including South Korea and South Africa.